PHIGENIX Appoints Michael C. Shores to Board of Directors

News Image

“We are excited to welcome Michael Shores to the Board of Directors. He brings a wealth of experience across numerous sectors, including healthcare.


Mr. Shores is currently an Entrepreneur in Residence for Quark Ventures and has more than 27 years of experience in all phases of operations. Mr. Shores is an accomplished entrepreneurial executive with a keen business sense for emerging products and services that require innovative introduction, unconventional selling and consumer shifts. He is a leader in product realization, having assisted top tier Fortune 500 companies think through, target and realize their competitive advantage through product development. Mr. Shores has secured millions of dollars in investments from strategic partners including FLEX, Foxconn and Nokia-Siemens, and has launched more than $1.5 billion USD of products into the global marketplace. Mr. Shores has extensive in-country experience in both China and India. He also wrote the forward for the book “How to Win in China,” by Stephen P. Turner, M.A. Most recently, Mr. Shores has been advancing artificial intelligence technology in the healthcare sector to increase efficiency in federally mandated hospital communications, reducing the high cost of readmissions and ultimately improving outcomes for patients.

Dr. Carlton Donald, CEO of PHIGENIX, commented, “We are excited to welcome Michael Shores to the Board of Directors. He brings a wealth of experience across numerous sectors, including healthcare. In particular, he brings extensive product development and commercialization experience, which will be invaluable as we enter the next phase of our growth.”

Michael Shores commented, “I am excited to join the board of PHIGENIX, given its break through diagnostics and targeted therapies in the fields of prostate and breast cancer. Dr. Carlton Donald is a true pioneer in this field with over 20 years of experience as a cancer researcher and bringing new technologies to market. Early detection is the key to long-term survival, and I truly believe PHIGENIX’s platform technologies have the potential to save countless lives. I look forward to leveraging my experience and relationships in order to accelerate development and commercialization of these exciting programs.”

PHIGENIX INC ( is developing ground-breaking technology in personalized medicine consisting of novel therapeutic targets and companion diagnostic tests. Our lead biomarker and target has been validated in prostate cancer and Her2-positive breast cancer patients, and several recent independent studies support our technology. We have successfully built a robust patent portfolio to protect our IP and have successfully defended the validity of one of our key patents. We have initiated talks with pharmaceutical and biotech companies for possible licensing.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit

Phigenix, Inc.
191 Peachtree Street, NW
Suite 3200
Atlanta, GA 30303

Powered by WPeMatico